Compare MVST & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | DRUG |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.0M | 228.0M |
| IPO Year | 2019 | 2020 |
| Metric | MVST | DRUG |
|---|---|---|
| Price | $0.21 | $20.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.00 | ★ $107.47 |
| AVG Volume (30 Days) | ★ 5.5M | 263.1K |
| Earning Date | 11-09-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $427,516,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $0.20 | $17.40 |
| 52 Week High | $3.88 | $123.75 |
| Indicator | MVST | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 29.12 | 26.33 |
| Support Level | $0.20 | $17.40 |
| Resistance Level | $0.71 | $58.93 |
| Average True Range (ATR) | 0.05 | 3.39 |
| MACD | -0.04 | -0.58 |
| Stochastic Oscillator | 1.76 | 7.04 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.